These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 32449213)

  • 21. Effects of Lasmiditan on Cardiovascular Parameters and Pharmacokinetics in Healthy Subjects Receiving Oral Doses of Propranolol.
    Tsai M; Case M; Ardayfio P; Hochstetler H; Wilbraham D
    Clin Pharmacol Drug Dev; 2020 Jul; 9(5):629-638. PubMed ID: 31950732
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials.
    Shapiro RE; Hochstetler HM; Dennehy EB; Khanna R; Doty EG; Berg PH; Starling AJ
    J Headache Pain; 2019 Aug; 20(1):90. PubMed ID: 31464581
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety Findings in Lasmiditan as a Novel Acute Treatment of Migraine in Chinese Patients: A Post Hoc Analysis of the Randomized Controlled Phase 3 CENTURION Trial.
    Zhou J; Luo G; Xu Y; Yang X; Pan X; Dong Z; Zhong S; Liu H; Ji F; Yu S
    Adv Ther; 2022 Nov; 39(11):5229-5243. PubMed ID: 36114949
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lasmiditan for the acute treatment of migraine.
    Tepper D
    Headache; 2020 Jun; 60(6):1225-1226. PubMed ID: 32474924
    [No Abstract]   [Full Text] [Related]  

  • 25. Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans.
    Knievel K; Buchanan AS; Lombard L; Baygani S; Raskin J; Krege JH; Loo LS; Komori M; Tobin J
    Cephalalgia; 2020 Jan; 40(1):19-27. PubMed ID: 31744319
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lasmiditan: First Approval.
    Lamb YN
    Drugs; 2019 Dec; 79(18):1989-1996. PubMed ID: 31749059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase 2 randomized placebo-controlled study of lasmiditan for the acute treatment of migraine in Japanese patients.
    Sakai F; Takeshima T; Homma G; Tanji Y; Katagiri H; Komori M
    Headache; 2021 May; 61(5):755-765. PubMed ID: 33990951
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Profiling lasmiditan as a treatment option for migraine.
    Curto M; Cipolla F; Cisale GY; Capi M; Spuntarelli V; Guglielmetti M; Martelletti P; Lionetto L
    Expert Opin Pharmacother; 2020 Feb; 21(2):147-153. PubMed ID: 31766908
    [No Abstract]   [Full Text] [Related]  

  • 29. Efficacy and Safety of Lasmiditan for Acute Treatment of Migraine in Adults: A Meta-Analysis.
    Maiti R; Mishra A; Puliappadamb HM; Jena M; Srinivasan A
    J Clin Pharmacol; 2021 Dec; 61(12):1534-1544. PubMed ID: 34472095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lasmiditan for the treatment of migraine.
    Capi M; de Andrés F; Lionetto L; Gentile G; Cipolla F; Negro A; Borro M; Martelletti P; Curto M
    Expert Opin Investig Drugs; 2017 Feb; 26(2):227-234. PubMed ID: 28076702
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting the 5-HT
    Huang PC; Yang FC; Chang CM; Yang CP
    Prog Brain Res; 2020; 255():99-121. PubMed ID: 33008517
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Efficacy of Lasmiditan for the Treatment of Migraine: A Meta-Analysis of Randomized Controlled Studies.
    Zhu H; Tang Y; Zhou T; Song J
    Clin Neuropharmacol; 2020; 43(6):191-195. PubMed ID: 32969971
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tolerability and Safety of Lasmiditan Treatment in Elderly Patients With Migraine: Post Hoc Analyses From Randomized Studies.
    Martin VT; Ahmed Z; Hochstetler HM; Baygani SK; Dong Y; Hauck PM; Khanna R
    Clin Ther; 2021 Jun; 43(6):1066-1078. PubMed ID: 34366152
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecule of the month. Lasmiditan hydrochloride.
    Drug News Perspect; 2010 Sep; 23(7):455. PubMed ID: 20862397
    [No Abstract]   [Full Text] [Related]  

  • 35. Exploration of Lasmiditan 200 mg Versus 100 mg for the Treatment of Migraine: A Meta-analysis Based on Aggregate Data.
    Wang T; Feng Y
    Clin Neuropharmacol; 2024 Mar-Apr 01; 47(2):44-47. PubMed ID: 38478364
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting to 5-HT1F receptor subtype for migraine treatment: lessons from the past, implications for the future.
    Mitsikostas DD; Tfelt-Hansen P
    Cent Nerv Syst Agents Med Chem; 2012 Dec; 12(4):241-9. PubMed ID: 22934751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Migraine history and response to lasmiditan across racial and ethnic groups.
    Charleston L; Savage-Edwards B; Bragg SM; Baygani SK; Dennehy EB
    Curr Med Res Opin; 2022 May; 38(5):721-730. PubMed ID: 35350937
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 5-HT1F agonists.
    Steel SJ
    Handb Clin Neurol; 2024; 199():43-50. PubMed ID: 38307661
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drugs targeting 5-hydroxytryptamine receptors in acute treatments of migraine attacks. A review of new drugs and new administration forms of established drugs.
    Tfelt-Hansen PC; Pihl T; Hougaard A; Mitsikostas DD
    Expert Opin Investig Drugs; 2014 Mar; 23(3):375-85. PubMed ID: 24289494
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety findings from CENTURION, a phase 3 consistency study of lasmiditan for the acute treatment of migraine.
    Tassorelli C; Bragg S; Krege JH; Doty EG; Ardayfio PA; Ruff D; Dowsett SA; Schwedt T
    J Headache Pain; 2021 Nov; 22(1):132. PubMed ID: 34742230
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.